ROCKVILLE, Md., March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy...
Read More Details
Finally We wish PressBee provided you with enough information of ( REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference )
Also on site :
- Ukrainian teachers told to pretend they can’t speak Russian
- Couple Bring Cat To Vet, Realize Something Heartbreaking Once They Arrive
- Kylie Jenner’s Stunning European Vacation Snapshots Are Giving Us Major Life Goals Envy